Platelet-derived sphingosine-1-phosphate and inflammation: from basic mechanisms to clinical implications

Platelets

Volumn 27, Issue 5, 2016, Pages 393-401

  Vito, Clara Di ^a   Hadi, Loubna Abdel ^a   Navone, Stefania Elena ^a   Marfia, Giovanni ^a   Campanella, Rolando ^a   Mancuso, Maria Elisa ^b   Riboni, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Inflammation; platelets; sphingosine 1 phosphate

Indexed keywords

SPHINGOSINE 1 PHOSPHATE; ANTIINFLAMMATORY AGENT; LYSOPHOSPHOLIPID; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ATHEROSCLEROSIS; AUTOCRINE EFFECT; BLOOD CELL; ENDOTHELIUM CELL; GLOMERULONEPHRITIS; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE; METABOLISM; PARACRINE SIGNALING; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; THROMBOCYTE; THROMBOCYTE ACTIVATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; HUMAN; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; THROMBOSIS; TRANSPORT AT THE CELLULAR LEVEL; VASCULAR ENDOTHELIUM;

ANTI-INFLAMMATORY AGENTS; AUTOCRINE COMMUNICATION; BIOLOGICAL TRANSPORT; BLOOD PLATELETS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; LEUKOCYTES; LYSOPHOSPHOLIPIDS; MOLECULAR TARGETED THERAPY; PLATELET ACTIVATION; SIGNAL TRANSDUCTION; SPHINGOSINE; THROMBOSIS;

EID: 84961215971     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2016.1144179     Document Type: Review

References (138)

1. K.R.Machlus, I.J.E.JrItaliano JE. The incredible journey: From megakaryocyte development to platelet formation. J Cell Biol 2013;201:785–796.
2. E.M.Golebiewska, A.W.Poole Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev 2015;29:153–162.
3. J.D.McFadyen, S.P.Jackson Differentiating haemostasis from thrombosis for therapeutic benefit. Thromb Haemos 2013;110:859–867.
4. R.K.Andrews, M.C.Berndt Platelet adhesion: A game of catch and release. J Clin Invest 2008;118:3009–3011.
5. S.P.Jackson, W.S.Nesbitt, E.Westein Dynamics of platelet thrombus formation. Thromb Haemost 2009;1:17–20.
6. Z.Li, M.K.Delaney, K.A.O’Brien, X.Du Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010;30:2341–2349.
7. J.D.McFadyen, Z.S.Kaplan Platelets are not just for clots. Transfus Med Rev 2015;29:110–119.
8. J.M.Herter, J.Rossaint, A.Zarbock Platelets in inflammation and immunity. J Thromb Haemost 2014;12:1764–1775.
9. A.Gros, V.Ollivier, B.Ho-Tin-Noé Platelets in inflammation: Regulation of leukocyte activities and vascular repair. Front Immunol 2015;5:678.
10. C.N.Jenne, P.Kubes Platelets in inflammation and infection. Platelets 2015;26:286–292.
11. N.Li Platelet-lymphocyte cross-talk. J Leukoc Biol 2008;83:1069–1078.
12. J.Stephen, B.Emerson, K.A.Fox, I.Dransfield The uncoupling of monocyte-platelet interactions from the induction of proinflammatory signaling in monocytes. J Immunol 2013;191:5677–5683.
13. C.M.Scull, W.D.Hays, T.H.Fischer Macrophage pro-inflammatory cytokine secretion is enhanced following interaction with autologous platelets. J Inflamm (Lond) 2010;7:53.
14. G.M.Strub, M.Maceyka, N.C.Hait, S.Milstien, S.Spiegel Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 2010;688:141–155.
15. S.Pyne, S.C.Lee, J.Long, N.J.Pyne Role of sphingosine kinases and lipid phosphate phosphatases in regulating spatial sphingosine 1-phosphate signalling in health and disease. Cell Signal 2009;21:14–21.
16. X.Liu, Q.H.Zhang, G.H.Yi Regulation of metabolism and transport of sphingosine-1-phosphate in mammalian cells. Mol Cell Biochem 2012;363:21–33.
17. G.Tettamanti, R.Bassi, P.Viani, L.Riboni Salvage pathways in glycosphingolipid metabolism. Biochimie 2003;85:423–437.
18. Y.A.Hannun, L.M.Obeid Principles of bioactive lipid signalling: Lessons from sphingolipids. Nature Rev Mol Cell Biol 2008;9:139–150.
19. K.Takabe, S.W.Paugh, S.Milstien, S.Spiegel “Inside-out” signaling of sphingosine-1-phosphate: Therapeutic targets. Pharmacol Rev 2008;60:181–195.
20. M.Maceyka, K.B.Harikumar, S.Milstien, S.Spiegel Sphingosine-1-phosphate signalling and its role in disease. Trends Cell Biol 2012;22:50–60.
21. L.Riboni, P.Giussani, P.Viani Sphingolipid transport. Adv Exp Med Biol 2010;688:24–45.
22. T.Nishi, N.Kobayashi, Y.Hisano, Y.A.Kawahara Atsuo, Yamaguchi A. Molecular and physiological functions of sphingosine 1-phosphate transporters. Biochim Biophys Acta 2014;1841:759–765.
23. R.H.Kim, K.Takabe, S.Milstien, S.Spiegel Export and functions of sphingosine-1-phosphate. Biochim Biophys Acta 2009;1791:692–696.
24. V.A.Blaho, T.Hla An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res 2014;55:1596–1608.
25. R.L.Proia, T.Hla Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest 2015;125:1379–1387.
26. M.Serra, J.D.Saba Sphingosine 1-phosphate lyase, a key regulator of sphingosine 1-phosphate signaling and function. Adv Enzyme Regul 2010;50:349–362.
27. S.M.Mandala Sphingosine-1-phosphate phosphatases. Prostaglandins Other Lipid Mediat 2001;64:143–156.
28. X.Tang, M.G.K.Benesch, D.N.Brindley Lipid phosphate phosphatases and their roles in mammalian physiology and pathology. J Lipid Res 2015;56:2048–2060.
29. M.Książek, M.Chacińska, A.Chabowski, B.M.SourcesBaranowski M., metabolism, and regulation of circulating sphingosine-1-phosphate. J Lipid Res 2015;56:1271–1281.
30. C.Christoffersen, H.Obinata, S.B.Kumaraswamy, S.Galvani, J.Ahnström, M.Sevvana, C.Egerer-Sieber, Y.A.Muller, T.Hla, L.B.Nielsen, et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011;108:9613–9618.
31. N.Murata, K.Sato, J.Kon, H.Tomura, M.Yanagita, A.Kuwabara, M.Ui, F.Okajima Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000;352:809–815.
32. F.Okajima Plasma lipoproteins behave as carriers of extracellular sphingosine 1-phosphate: is this an atherogenic mediator or an anti-atherogenic mediator? Biochim Biophys Acta 2002;1582:132–137.
33. Y.Yatomi, Y.Igarashi, L.Yang, N.Hisano, R.Qi, N.Asazuma, K.Satoh, Y.Ozaki, K.S.SphingosineKume S. 1-phosphate, a bioactive sphingolipid abundantly stored in platelets, is a normal constituent of human plasma and serum. J Biochem 1997;121:969–973.
34. P.Hänel, P.Andreani, M.H.Graler Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007;21:1202–1209.
35. C.Bode, S.C.Sensken, U.Peest, G.Beutel, F.Thol, B.Levkau, Z.Li, R.Bittman, T.Huang, M.Tolle, et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem 2010;109:1232–1243.
36. K.Venkataraman, Y.M.Lee, J.Michaud, S.Thangada, Y.Ai, H.L.Bonkovsky, N.S.Parikh, C.Habrukowich, T.Hla Vascular endothelium as a contributor of plasma sphingosine 1-phosphate. Circ Res 2008;102:669–676.
37. L.Yang, Y.Yatomi, Y.Miura, K.Satoh, Y.Ozaki Metabolism and functional effects of sphingolipids in blood cells. Br J Haematol 1999;107:282–293.
38. R.Ohkawa, K.Nakamura, S.Okubo, S.Hosogaya, Y.Ozaki, M.Tozuka, N.Osima, H.Yokota, H.Ikeda, Y.Yatomi Plasma sphingosine-1-phosphate measurement in healthy subjects: Close correlation with red blood cell parameters. Ann Clin Biochem 2008;45:356–363.
39. S.Fukuhara, S.Simmons, S.Kawamura, A.Inoue, Y.Orba, T.Tokudome, Y.Sunden, Y.Arai, K.Moriwaki, J.Ishida, et al. The sphingosine-1-phosphate transporter Spns2 expressed on endothelial cells regulates lymphocyte trafficking in mice. J Clin Invest 2012;122:1416–1426.
40. Y.Hisano, N.Kobayashi, A.Yamaguchi, T.Nishi Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS One 2012;7:e38941.
41. L.Zhang, N.Urtz, F.Gaertner, K.R.Legate, T.Petzold, M.Lorenz, A.Mazharian, S.P.Watson, S.Massberg Sphingosine kinase 2 (Sphk2) regulates platelet biogenesis by providing intracellular sphingosine 1-phosphate (S1P). Blood 2013;122:791–802.
42. L.Zhang, M.Orban, M.Lorenz, V.Barocke, D.Braun, N.Urtz, C.Schulz, M.L.von Brühl, A.Tirniceriu, F.Gaertner, et al. A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse thrombopoiesis. J Exp Med 2012;209:2165–2181.
43. T.Hla, S.Galvani, S.Rafii, R.Nachman S1P and the birth of platelets. J Exp Med 2012;209:2137–2140.
44. S.Golfier, S.Kondo, T.Schulze, T.Takeuchi, G.Vassileva, A.H.Achtman, M.H.Graler, S.J.Abbondanzo, M.Wiekowski, E.Kremmer, et al. Shaping of terminal megakaryocyte differentiation and proplatelet development by sphingosine-1-phosphate receptor S1P4. FASEB J 2010;24:4701–4710.
45. B.H.Rauch Sphingosine 1-phosphate as a link between blood coagulation and inflammation. Cell Physiol Biochem 2014;34:185–196.
46. H.Obinata, H.T.SphingosineHla T. 1-phosphate in coagulation and inflammation. Semin Immunopathol 2012;34:73–91.
47. Y.Yatomi, F.Ruan, S.Hakomori, Y.Igarashi Sphingosine-1-phosphate: A platelet-activating sphingolipid released from agonist-stimulated human platelets. Blood 1995;86:193–202.
48. V.Randriamboavonjy, K.Badenhoop, H.Schmidt, G.Geisslinger, B.Fisslthaler, I.Fleming The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes. Basic Res Cardiol 2009;104:333–340.
49. H.Xiao, R.A.Siddiqui, M.H.Al-Hassani, D.Sliva, R.J.Kovacs Phospholipids released from activated platelets improve platelet aggregation and endothelial cell migration. Platelets 2001;12:163–170.
50. N.Urtz, F.Gaertner, M.L.von Bruehl, S.Chandraratne, F.Rahimi, L.Zhang, M.Orban, V.Barocke, J.Beil, I.Schubert, et al. Sphingosine 1-phosphate produced by sphingosine kinase 2 intrinsically controls platelet aggregation in vitro and in vivo. Circ Res 2015;117:376–387.
51. D.Nugent, Y.Xu Sphingosine-1-phosphate: Characterization of its inhibition of platelet aggregation. Platelets 2000;11:226–232.
52. W.Stoffel, G.Heimann, B.Hellenbroich Sphingosine kinase in blood platelets. Hoppe Seylers Z Physiol Chem 1973;354:562–566.
53. Y.Yatomi, S.Yamamura, F.Ruan, I.Y.SphingosineIgarashi Y. 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. J Biol Chem 1997;272:5291–5297.
54. Y.Yatomi, Y.Ozaki, T.Ohmori, I.Y.SphingosineIgarashi Y. 1-phosphate: Synthesis and release. Prostaglandins Other Lipid Mediat 2001;64:107–122.
55. M.Tani, T.Sano, M.Ito, Y.Igarashi Mechanisms of sphingosine and sphingosine 1-phosphate generation in human platelets. J Lipid Res 2005;46:2458–2467.
56. A.J.Marcus, H.L.Ullman, L.B.Safier Lipid composition of subcellular particles of human blood platelets. J Lipid Res 1969;10:108–114.
57. I.Tabas Secretory sphingomyelinase. Chem Phys Lipids 1999;102:123–130.
58. 2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J Biol Chem 1996;271:18431–18436.
59. S.Marathe, S.L.Schissel, M.J.Yellin, N.Beatini, R.Mintzer, K.J.Williams, I.Tabas Human vascular endothelial cells are a rich and regulatable source of secretory sphingomyelinase. Implications for early atherogenesis and ceramide-mediated cell signaling. J Biol Chem 1998;273:4081–4088.
60. E.Romiti, V.Vasta, E.Meacci, M.Farnararo, T.Linke, K.Ferlinz, K.Sandhoff, P.Bruni Characterization of sphingomyelinase activity released by thrombin-stimulated platelets. Mol Cell Biochem 2000;205:75–81.
61. E.Romiti, E.Meacci, M.Tani, F.Nuti, M.Farnararo, M.Ito, P.Bruni Neutral/alkaline and acid ceramidase activities are actively released by murine endothelial cells. Biochem Biophys Res Commun 2000;275:746–751.
62. B.Engelmann, C.Kögl, R.Kulschar, B.Schaipp Transfer of phosphatidylcholine, phosphatidylethanolamine and sphingomyelin from low- and high-density lipoprotein to human platelets Biochem J 1996;315:781–789.
63. S.C.G.JrSimon CG, S.Chatterjee, A.R.Gear Sphingomyelinase activity in human platelets. Thromb Res 1998;90:155–161.
64. Y.Fukuda, A.Kihara, Y.Igarashi Distribution of sphingosine kinase activity in mouse tissues: contribution of SPHK1. Biochem Biophys Res Commun 2003;309:155–160.
65. Y.Banno, M.Kato, A.Hara, Y.Nozawa Evidence for the presence of multiple forms of Sph kinase in human platelets. Biochem J 1998;335:301–304.
66. N.Kobayashi, T.Nishi, T.Hirata, A.Kihara, T.Sano, Y.Igarashi, Y.A.SphingosineYamaguchi A. 1-phosphate is released from the cytosol of rat platelets in a carrier-mediated manner. J Lipid Res 2006;47:614–621.
67. D.Jonnalagadda, M.Sunkara, A.J.Morris, S.W.Whiteheart Granule-mediated release of sphingosine-1-phosphate by activated platelets. Biochim Biophys Acta 2014;1841:1581–1589.
68. S.S.Smyth, V.A.Sciorra, Y.J.Sigal, Z.Pamuklar, Z.Wang, Y.Xu, G.D.Prestwich, A.J.Morris Lipid phosphate phosphatases regulate lysophosphatidic acid production and signalling in platelets: studies using chemical inhibitors of lipid phosphate phosphatase activity. J Biol Chem 2003;278:43214–43223.
69. Y.Ono, M.Kurano, R.Ohkawa, H.Yokota, K.Igarashi, J.Aoki, M.Tozuka, Y.Y.SphingosineYatomi Y. 1-phosphate release from platelets during clot formation: Close correlation between platelet count and serum sphingosine 1-phosphate concentration. Lipids Health Dis 2013;12:20–26.
70. T.Ulrych, A.Böhm, A.Polzin, G.Daum, R.M.Nüsing, G.Geisslinger, T.Hohlfeld, K.Schrör, B.H.Rauch Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost 2011;9:790–798.
71. T.Sano, D.Baker, T.Virag, A.Wada, Y.Yatomi, T.Kobayashi, Y.Igarashi, G.Tigyi Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in blood. J Biol Chem 2002;277:21197–21206.
72. Y.Anada, Y.Igarashi, A.Kihara The immunomodulator FTY720 is phosphorylated and released from platelets. Eur J Pharmacol 2007;568:106–111.
73. C.Frej, A.Andersson, B.Larsson, L.J.Guo, E.Norström, K.E.Happonen, B.Dahlbäck Quantification of sphingosine 1-phosphate by validated LC-MS/MS method revealing strong correlation with apolipoprotein M in plasma but not in serum due to platelet activation during blood coagulation. Anal Bioanal Chem 2015;407:8533–8542.
74. S.Aoki, Y.Yatomi, M.Ohta, M.Osada, F.Kazama, K.Satoh, K.Nakahara, O.Y.SphingosineOzaki Y. 1-phosphate-related metabolism in the blood vessel. J Biochem 2005;138:47–55.
75. B.A.Wilkerson, G.D.Grass, S.B.Wing, W.S.Argraves, K.M.Argraves Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: High density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J Biol Chem 2012;287:44645–44653.
76. M.Maceyka, S.Spiegel Sphingolipid metabolites in inflammatory disease. Nature 2014;510:58–67.
77. R.W.Jenkins, D.Canals, J.Idkowiak-Baldys, F.Simbari, P.Roddy, D.M.Perry, K.Kitatani, C.Luberto, Y.A.Hannun Regulated secretion of acid sphingomyelinase: Implications for selectivity of ceramide formation. J Biol Chem 2010;285:35706–35718.
78. S.C.G.JrSimon CG, S.Chatterjee, Gear AR Sphingomyelinase activity in human platelets. Thromb Res 1998;90:155–161.
79. M.L.Wong, B.Xie, N.Beatini, P.Phu, S.Marathe, A.Johns, P.W.Gold, E.Hirsch, K.J.Williams, J.Licinio, et al. Acute systemic inflammation up-regulates secretory sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 2000;97:8681–8686.
80. J.Kornhuber, C.Rhein, C.P.Müller, C.Mühle Secretory sphingomyelinase in health and disease. Biol Chem 2015;396:707–736.
81. M.Naghavi, R.John, S.Naguib, M.S.Siadaty, R.Grasu, K.C.Kurian, W.B.van Winkle, B.Soller, S.Litovsky, M.Madjid, et al. pH heterogeneity of human and rabbit atherosclerotic plaques; a new insight into detection of vulnerable plaque. Atherosclerosis 2002;164:27–35.
82. M.Sneck, S.D.Nguyen, T.Pihlajamaa, G.Yohannes, M.L.Riekkola, R.Milne, P.T.Kovanen, K.Oörni Conformational changes of apoB-100 in SMase-modified LDL mediate formation of large aggregates at acidic pH. J Lipid Res 2012;53:1832–1839.
83. W.-F.Chen, J.-J.Lee, C.-C.Chang, K.-H.Lin, H.Wang, J.-R.Sheu Platelet protease-activated receptor (PAR)4, but not PAR1, associated with neutral sphingomyelinase responsible for thrombin-stimulated ceramide-NF-κB signaling in human platelets. Haematol 2013;98:793–801.
84. F.Setzer, V.Oberle, M.Bläss, E.Möller, S.Russwurm, H.P.Deigner, R.A.Claus, M.Bauer, K.Reinhart, W.Lösche Platelet-derived microvesicles induce differential gene expression in monocytic cells: a DNA microarray study. Platelets 2006;17:571–576.
85. M.J.Kluk, T.Hla Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim Biophys Acta 2002;1582:72–80.
86. T.Goerge, B.Ho-Tin-Noe, C.Carbo, C.Benarafa, E.Remold-O’Donnell, B.Q.Zhao, S.M.Cifuni, D.D.Wagner Inflammation induces haemorrhage in thrombocytopenia. Blood 2008;111:4958–4964.
87. S.Lucke, B.Levkau Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem 2010;26:87–96.
88. Y.Yatomi, T.Ohmori, G.Rile, F.Kazama, H.Okamoto, T.Sano, K.Satoh, S.Kume, G.Tigyi, Y.Igarashi, et al. Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 2000;96:3431–3438.
89. Y.Xiong, T.Hla S1P control of endothelial integrity. Curr Top Microbiol Immunol 2014;378:85–105.
90. J.G.Garcia, F.Liu, A.D.Verin, A.Birukova, M.A.Dechert, W.T.Gerthoffer, J.R.Bamberg, E.D.SphingosineEnglish D. 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 2001;108:689–701.
91. K.L.Schaphorst, E.Chiang, K.N.Jacobs, A.Zaiman, V.Natarajan, F.Wigley, J.G.Garcia Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products. Am J Physiol Lung Cell Mol Physiol 2003;285:L258–L267.
92. D.English, J.G.Garcia, D.N.Brindley Platelet-released phospholipids link haemostasis and angiogenesis. Cardiovasc Res 2001;49:588–599.
93. T.G.Walsh, P.Metharom, M.C.Berndt The functional role of platelets in the regulation of angiogenesis. Platelets 2015;26:199–211.
94. B.H.1.Herzog, J.Fu, W.SJWilson, H.PRHess, A.Sen, M.JMMcDaniel, Y.Pan, M.Sheng, T.Yago, R.Silasi-Mansat, et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature. 2013;502:105–109.
95. C.I.Lin, C.N.Chen, P.W.Lin, L.H.SphingosineLee H. 1-phosphate regulates inflammation-related genes in human endothelial cells through S1P1 and S1P3. Biochem Biophys Res Commun 2007;355:895–901.
96. J.Iino, M.Osada, M.Kurano, M.Kaneko, R.Ohkawa, Y.Satoh, S.Okubo, Y.Ozaki, M.Tozuka, N.H.Tsuno, Y.Yatomi Platelet-derived sphingosine 1-phosphate induces migration of Jurkat T cells. Lipids Health Dis 2014;13:150.
97. O.Florey, D.O.Haskard Sphingosine 1-phosphate enhances Fc gamma receptor-mediated neutrophil activation and recruitment under flow conditions. J Immunol 2009;183:2330–2336.
98. S.Mahajan-Thakur, B.D.Sostmann, A.C.Fender, D.Behrendt, S.B.Felix, K.Schrör, B.H.Rauch Sphingosine-1-phosphate induces thrombin receptor PAR-4 expression to enhance cell migration and COX-2 formation in human monocytes. J Leukoc Biol 2014;96:611–618.
99. E.Q.Fuentes, F.Q.Fuentes, V.Andrés, O.M.Pello, Font de Mora J, Palomo IG. Role of platelets as mediators that link inflammation and thrombosis in atherosclerosis. Platelets 2013;24:255–262.
100. H.M.Nording, P.Seizer, H.F.Langer Platelets in inflammation and atherogenesis. Front Immunol 2015;6:98.
101. G.Daum, A.Grabski, M.A.Reidy Sphingosine 1-phosphate: A regulator of arterial lesions. Arterioscler Thromb Vasc Biol 2009;29:1439–1443.
102. F.Potì, M.Simoni, J.R.Nofer Atheroprotective role of high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P). Cardiovasc Res 2014;103:395–404.
103. K.Shimamura, Y.Takashiro, N.Akiyama, T.Hirabayashi, T.Murayama Expression of adhesion molecules by sphingosine 1-phosphate and histamine in endothelial cells. Eur J Pharmacol 2004;486:141–150.
104. H.Kase, Y.Hattori, T.Jojima, T.Okayasu, A.Tomizawa, K.Suzuki, N.Banba, T.Monden, H.Satoh, K.Akimoto, K.Kasai Globular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cells. Life Sci 2007;81:939–943.
105. S.Galvani, M.Sanson, V.A.Blaho, S.L.Swendeman, H.Conger, B.Dahlbäck, M.Kono, R.L.Proia, J.D.Smith, T.Hla HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal. 2015;11;8(389):ra79.
106. D.H.Deutschman, J.S.Carstens, R.L.Klepper, W.S.Smith, M.T.Page, T.R.Young, L.A.Gleason, N.Nakajima, R.A.Sabbadini Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003;146:62–68.
107. D.J.Son, H.W.Lee, H.W.Shin, J.J.Lee, H.S.Yoo, T.J.Kim, Y.P.Yun, J.T.Hong Enhanced release of sphingosine-1-phosphate from hypercholesterolemic platelets: Role in development of hypercholesterolemic atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 2008;78:383–390.
108. P.Münzer, O.Borst, B.Walker, E.Schmid, M.A.Feijge, J.M.Cosemans, M.Chatterjee, E.M.Schmidt, S.Schmidt, S.T.Towhid, et al. Acid sphingomyelinase regulates platelet cell membrane scrambling, secretion, and thrombus formation. Arterioscler Thromb Vasc Biol 2014;34:61–71.
109. A.Sugiyama, Y.Yatomi, Y.Ozaki, H.K.SphingosineHashimoto K. 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 2000;46:119–125.
110. T.Ohmori, Y.Yatomi, M.Osada, Y.Ozaki Platelet-derived sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. J Thromb Haemost 2004;2:203–205.
111. J.R.Nofer, M.Bot, M.Brodde, P.J.Taylor, P.Salm, V.Brinkmann, T.van Berkel, G.Assmann, E.A.Biessen FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007;115:501–508.
112. P.Keul, M.Tölle, S.Lucke, K.von Wnuck Lipinski, G.Heusch, M.Schuchardt, M.van der Giet, B.Levkau The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2007;27:607–613.
113. J.Varga, D.Abraham Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557–567.
114. D.Pattanaik, M.Brown, B.C.Postlethwaite, Postlethwaite AE Pathogenesis of Systemic Sclerosis. Front Immunol 2015;6:272.
115. S.Bhattacharyya, J.Wei, J.Varga Understanding fibrosis in systemic sclerosis: Shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2011;8:42–54.
116. N.Maugeri, P.Rovere-Querini, M.Baldini, E.Baldissera, M.G.Sabbadini, M.E.Bianchi, A.A.Manfredi Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: A candidate for microvessel injury in sytemic sclerosis. Antioxid Redox Signal 2014;20:1060–1074.
117. A.E.Postlethwaite, T.M.Chiang Platelet contributions to the pathogenesis of systemic sclerosis. Curr Opin Rheumatol 2007;19:574–579.
118. G.A.Ramirez, S.Franchini, P.Rovere-Querini, M.G.Sabbadini, A.A.Manfredi, N.Maugeri The role of platelets in the pathogenesis of systemic sclerosis. Front Immunol 2012;3:160.
119. D.Pattanaik, A.E.Postlethwaite A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov Med 2010;10:161–167.
120. A.Tokumura, L.D.Carbone, Y.Yoshioka, J.Morishige, M.Kikuchi, A.Postlethwaite, M.A.Watsky Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 2009;6:168–176.
121. D.Pattanaik, M.Brown, A.E.Postlethwaite Vascular involvement in systemic sclerosis (scleroderma). J Inflam Res 2011;4:105–125.
122. S.Bu, Y.Asano, A.Bujor, K.Highland, F.Hant, T.M.DihydrosphingosineTrojanowska M. 1-phosphate has a potent antifibrotic effect in scleroderma fibroblasts via normalization of phosphatase and tensin homolog levels. Arthritis Rheum 2010;62:2117–2126.
123. W.G.Couser Pathogenesis of glomerular damage in glomerulonephritis. Nephrol Dial Transplant 1998;13:10–15.
124. J.L.Barnes Platelets in glomerular disease. Nephron 1997;77:378–393.
125. R.Johnson, H.Iida, A.Yoshimura, J.Floege, D.F.Bowen-Pope Platelet-derived growth factor: a potentially important cytokine in glomerular disease. Kidney Int 1992;41:590–594.
126. C.Schwarzenberger, J.Sradnick, K.M.Lerea, M.S.Goligorsky, B.Nieswandt, C.P.Hugo, B.Hohenstein Platelets are relevant mediators of renal injury induced by primary endothelial lesions. Am J Physiol Renal Physiol 2015;308:F1238–F1246.
127. A.Koch, J.Pfeilschifter, H.A.SphingosineHuwiler A. 1-Phosphate in Renal Diseases. Cell Physiol Biochem 2013;31:745–760.
128. S.Schwalm, J.Pfeilschifter, A.Huwiler Targeting the sphingosine kinase/sphingosine 1-phosphate pathway to treat chronic inflammatory kidney diseases. Basic Clin Pharmacol Toxicol 2014;114:44–49.
129. R.J.Johnson, R.L.Garcia, P.Pritzl, C.E.Alpers Platelets mediate glomerular cell proliferation in immune complex nephritis induced by anti-mesangial cell antibodies in the rat. Am J Pathol 1990;136:369–374.
130. N.Hanafusa, Y.Yatomi, K.Yamada, Y.Hori, M.Nangaku, T.Okuda, T.Fujita, K.Kurokawa, F.M.SphingosineFukagawa M. 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol Dial Transplant 2002;17:580–586.
131. S.Katsuma, S.Shiojima, A.Hirasawa, Y.Suzuki, K.Takagaki, M.Murai, Y.Kaminishi, Y.Hada, M.Koba, E.Muso, et al. Genomic analysis of a mouse model of immunoglobulin A nephropathy reveals an enhanced PDGF-EDG5 cascade. Pharmacogenomics J 2001;1:211–217.
132. M.Osada, Y.Yatomi, T.Ohmori, S.Aoki, S.Hosogaya, Y.Ozaki Involvement of sphingosine 1-phosphate, a platelet-derived bioactive lipid, in contraction of mesangium cells. J Biochem 2007;142:351–355.
133. R.J.Johnson, C.E.Alpers, P.Pritzl, M.Schulze, P.Baker, C.Pruchno, W.G.Couser Platelets mediate neutrophil-dependent immune complex nephritis in the rat. J Clin Invest 1988;82:1225–1235.
134. C.R.Zachem, C.E.Alpers, W.Way, S.J.Shankland, W.G.Couser, R.J.Johnson A role for P-selectin in neutrophil and platelet infiltration in immune complex glomerulonephritis. J Am Soc Nephrol 1997;8:1838–1844.
135. Y.Yatomi, F.Ruan, T.Megidish, T.Toyokuni, S.Hakomori, Y.Igarashi N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. Biochemistry 1996;35:626–633.
136. H.Deguchi, S.Yegneswaran, J.H.Griffin Sphingolipids as bioactive regulators of thrombin generation. J Biol Chem 2004;279:12036–12042.
137. S.Martini, S.Krämer, T.Loof, Y.W.Rosenke, U.Daig, K.Budde, H.-H.Neumayer, H.Peters S1P modulator FTY720 limits matrix expansion in acute anti-thy1 mesangioproliferative glomerulonephritis. Am J Physiol Renal Physiol 2007;292:F1761–F1770.
138. V.Brinkmann, B.ABillich, B.TBaumruker, P.Heining, R.Schmouder, G.Francis, S.Aradhye, P.Burtin Fingolimod (FTY720): Discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010;9:883–897.